TP53 and acute myeloid leukemia: Early clinical experiences in AML/MDS demonstrate pharmacodynamic on-target activity (nuclear re-accumulation of NPM1c/p53; HOX/MEIS down-titration) and signals of efficacy in biomarker-enriched cohorts, but single-agent cytoreduction has been modest and durability appears combination-dependent.